TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options under clinical evaluation
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT04079179 (Cobimetinib for the Treatment of Refractory LCH): This study is open to children or adults with relapsed or refractory LCH or other newly diagnosed, relapsed, or refractory histiocytic disorders.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice